Evaluation of different combination of pam2CSK4, poly (I:C) and imiquimod enhance immune responses to H9N2 avian influenza antigen in dendritic cells and duck

PLoS One. 2022 Jul 19;17(7):e0271746. doi: 10.1371/journal.pone.0271746. eCollection 2022.

Abstract

Current commercial H9 avian influenza viruses (AIVs) vaccines cannot provide satisfactory antibody titers and protective immunity against AIVs in duck. Toll like receptors (TLR) ligand as AIVs adjuvants can activate dendritic cells to improve immune responses in multiple animals, while the studies were absent in duck. Therefore, we investigated TLR ligands pam2CSK4, poly (I:C) and/or imiquimod enhance immune responses to inactivated H9N2 avian influenza antigen (H9N2 IAIV) in peripheral blood monocyte-derived dendritic cells (MoDCs) and duck. In vitro, we observed that transcription factor NF-κB, Th1/Th2 type cytokines (IFN-γ, IL-2 and IL-6) and the ability of catching H9N2 IAIV antigen were significantly up-regulated when H9N2 IAIV along with TLR ligands (pam2CSK4, poly (I:C) and imiquimod, alone or combination) in duck MoDCs. Also, the best enhancement effects were showed in combination of pam2CSK4, poly (I:C) and imiquimod group, whereas IFN-α showed no significant enhancement in all experimental groups. In vivo, the results demonstrated that the percentages of CD4+/ CD8+ T lymphocytes, the levels of Th1/Th2 type cytokines and H9N2 HI titers were significant enhanced in combination of pam2CSK4, poly (I:C) and imiquimod group. However, pam2CSK4 alone or combining with imiquimod showed no enhancement or additive effects on Th1 cytokines (IFN-γ and IL-2), Th2 cytokines (IL-6) and HI titers in Muscovy duck, respectively. Taken together, our results concluded that not all TLR ligands showed enhancement of immune responses to H9N2 IAIV in duck. The combination of poly (I:C), imiquimod and pam2CSK4 that can be an effectively adjuvant candidate for H9N2 AIVs inactivated vaccine in duck, which provide novel insights in explore waterfowl vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Chickens
  • Cytokines
  • Dendritic Cells
  • Ducks
  • Humans
  • Imiquimod / pharmacology
  • Immunity
  • Influenza A Virus, H9N2 Subtype*
  • Influenza Vaccines*
  • Influenza in Birds*
  • Influenza, Human*
  • Interleukin-2
  • Interleukin-6
  • Oligopeptides
  • Poly I-C / pharmacology
  • Toll-Like Receptor 2 / agonists
  • Toll-Like Receptor 9 / agonists
  • Toll-Like Receptors

Substances

  • Adjuvants, Immunologic
  • Cytokines
  • Influenza Vaccines
  • Interleukin-2
  • Interleukin-6
  • Oligopeptides
  • Toll-Like Receptor 2
  • Toll-Like Receptor 9
  • Toll-Like Receptors
  • PAM2-CSK4
  • Poly I-C
  • Imiquimod

Grants and funding

This work was supported by the National Natural Sciences Foundation of China [grant number: 31902285]; Scientific and Technological Project of Henan Province [grant number: 222102110155]; and Natural Science Foundation of Henan [grant number: 202300410187].